Clinical Trial

Congrats to IAG on BSI ISO13485 re-certification for DYNAMIKA!

Congrats to IAG on BSI ISO13485 re-certification for DYNAMIKA!

Congrats to IAG on BSI ISO13485 re-certification for DYNAMIKA!

Congratulations to IAG’s technical and quality teams for holding successful audit meetings with British Standards Institute (BSI) and receiving ISO13485 re-certification.

‘Maintenance of the highest technical standards is paramount to our company’s DNA!’ said Prof. Dehmeshki, Chief Technology Officer.

‘At IAG, we work to bring both CFR21 part 11 and ISO13485 quality standards into our day-to-day service and technology development, thus providing our clients with highest possible level of quality,’ said Max Feltham, IAG’s Quality Manager.

IAG’s DYNAMIKA platform is a unique comprehensible software for robust imaging data management in multi-centre trial setting and central review. Uniquely in the clinical research services industry, this is one software system to control trial progress, conduct central reads and, when needed, use built-in AI for earlier read-outs and decision support.

Use of DYNAMIKA, compliant to the industry’s highest quality certification as an integral  part of our CFR21 part 11 clinical trial process, enables IAG teams to deliver high quality results, even when managing complex clinical trials that require use of advanced imaging, technical solutions and Artificial Intelligence.

Moreover, having ISO13485 certification enables IAG to develop and release into clinical use novel methodologies, such as our AI-powered histology tool or the newest endpoint for scleroderma DAVIX.

‘IAG brings artificial intelligence in a meaningful way to the imaging process. This is the future of imaging – drives down cost and improves quality of analysis.  As images are used more for statistically meaningful endpoints, IAG has proven, validated, AI algorithms. The IAG platform and service model fits exactly with pharma efforts to be digital organizations, allowing seamless data ingestion capabilities and real time data access for analysis and decision making.’, said Dr. Olga Kubassova, IAG’s CEO.

Congratulations to the team, who will continue following ISO13485 and 21 CFR Part 11 and proceed with powering the best of pharmaceutical development, from phase 1-4!

Read more: DYNAMIKA, drugdevelopment, clinicaltrials, medicaldevice, MRI, CT, X-ray, PET, immunoPET, SPECT, US, histology, and fluoroscopy, imaging,

Read more about IAG’s expertise in Your Therapeutic Area.

Reach our to imaging.experts@ia-grp.com

About IAG, Image Analysis Group

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.

The use of novel image analysis methodologies will allow the partners to address complex issues such as pseudo-progression and quantitatively measure the treatment response, thus deploying a truly precision medicine approach to accurately monitor patient outcomes.

IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

About ISO

ISO 13485, Medical devices — Quality management systems — Requirements for regulatory purposes, is the International Standard for quality management systems for the medical devices sector. Published in 2016, it is designed to work with other management systems in a way that is efficient and transparent. The standard, which is now in its third edition, received strong support from the FDA, in line with its drive for global convergence of medical device regulatory processes.

The announcement by the FDA that it will use ISO 13485 in replacing its current quality system regulation, is an important next step in the recognition this standard has already gained globally.

News

Just published: AI Scoring System for Histology Review in Ulcerative Colitis

Published in April 2024 in United European Gastroenterol Journal,

Meet IAG at DDW 2024: AI and Precision Medicine in Ulcerative Colitis

Digestive Disease Week (DDW) meeting, Washington 18-21 May 2024

Webinar: Role of Artificial Intelligence in Imaging of Osteoarthritis

Discuss role of medical imaging and AI in drug development and clinical practice.

Meet IAG’s Musculoskeletal Expert Team at OARSI’24

Join our team to discuss imaging and AI in osteoarthritis drug development.

Events

Efficacy of Apremilast on Whole-Body Inflammation Indices in Patients With PsA :Assessments by Whole-Body MRI in the Ph4 MOSAIC Study

Efficacy of Apremilast on Whole-Body Inflammation Indices in Patients With Psoriatic Arthritis: Assessments by Whole-Body Magnetic Resonance Imaging in the Phase 4 MOSAIC Study

Background:

Psoriatic arthritis (PsA) is characterized by various patterns of inflammatory arthritis, enthesitis, dactylitis, and spondylitis. Apremilast is an oral immunomodulating phosphodiesterase-4 inhibitor that is indicated for treatment of PsA. Whole-body magnetic resonance imaging (WB-MRI) allows assessment of joints and entheses of the entire body in one examination when using the Outcome Measures in Rheumatology Clinical Trial (OMERACT) MRI whole-body scoring system for inflammation in peripheral joints and entheses (MRI-WIPE), which has not previously been applied in a clinical trial. Here we evaluate the efficacy of apremilast 30 mg BID (APR) on peripheral inflammation indices as measured by WB-MRI.

Objectives:

To evaluate how APR affects inflammation in peripheral joints and entheses of patients with PsA as assessed by WB-MRI.

Methods:

The phase 4 MOSAIC study was a multicenter, single-arm, open-label study evaluating APR (either as monotherapy or in combination with stable methotrexate) in patients with active PsA (diagnosis ≥3 months but ≤5 years, meeting the CASPAR criteria for PsA) for treatment up to 48 weeks. WB-MRI was performed at baseline, Week 24, and Week 48. Images were read and adjudicated by 2 experienced readers who were blinded to time of acquisition and clinical information. From WB-MRI, changes in the total peripheral inflammation index (83 joints and 33 entheses) were calculated using the OMERACT MRI-WIPE scoring system, as were changes in separate enthesitis and joint inflammation WB-MRI indices (WIPE-enthesitis and WIPE-joint inflammation). Changes in the heel enthesitis inflammation index (HEMRIS),

the hip joint inflammation MRI index (HIMRISS), and the knee joint inflammation MRI index (KIMRISS) were explored.

Results:

Overall, 122 patients were enrolled and treated with APR; 55% were women, mean age was 47 years, and patients had a mean duration of PsA of 1.9 years. The least squares mean (95% CI) change from baseline in total WIPE score based on total peripheral inflammation index (including both joint and enthesitis inflammation) as assessed by WB-MRI was -3.49 (- 5.46, -1.52) at Week 24 and -4.06 (-6.39, -1.72) at Week 48, indicating significant improvement in peripheral inflammation (Figure). Significant improvements were also observed in the WIPE-joint inflammation scores at both Week 24 and 48, and in the WIPE- enthesitis scores at Week 48 (Figure). Both the heel enthesitis inflammation index (HEMRIS) and the hip joint inflammation MRI index (HIMRISS) showed little change, while the knee joint inflammation MRI index (KIMRISS) showed numerical, but not significant, improvement (Figure). No new safety signals were identified.

Conclusion:

Patients with PsA treated with APR experienced a significant reduction in total peripheral inflammation, including significant improvement in peripheral joint inflammation and enthesitis, as assessed by WB-MRI. Results highlight the efficacy of APR on inflammatory manifestations of PsA as well as the benefit of using WB-MRI as a measure of inflammatory disease activity.

Apremilast Reduces Inflammation in Patients With Psoriatic Arthritis.

Apremilast Reduces Inflammation as Measured by MRI of the Hand in Patients With Psoriatic Arthritis: Primary Results from the Phase 4 MOSAIC Study

Background:

Psoriatic arthritis (PsA) is characterized by inflammatory arthritis, enthesitis, dactylitis, and spondylitis. Apremilast is an oral immunomodulating phosphodiesterase-4 inhibitor approved for the treatment of PsA. The impact of apremilast on objective measures of inflammation and structural progression of PsA has not yet been characterized. Here, we evaluate the efficacy of apremilast 30 mg BID (APR) on inflammation measured by dedicated MRI of the hand.

Objectives:

To evaluate the efficacy of APR on inflammation and imaging outcomes and the safety profile of APR in this setting.

Methods:

MOSAIC (NCT03783026) was a phase 4, multicenter, single-arm, open-label study in patients (pts) with active PsA (≥3 months but ≤5 years since diagnosis, meeting CASPAR criteria for PsA) evaluating APR as monotherapy or in combination with stable methotrexate. Pts were treated with APR for 48 weeks and had MRI of the hand (contrast-enhanced) performed at baseline (BL), Week 24, and Week 48. All images were read and adjudicated by 2 experienced readers blinded to clinical information and time of acquisition. The primary endpoint was change from BL in the composite score of hand bone marrow edema (BME), synovitis, and tenosynovitis in fingers 2–5, as assessed by the PsA MRI Score (PsAMRIS) at Week 24. Total inflammation score, comprised of BME, synovitis, tenosynovitis, and periarticular inflammation in fingers, was also assessed. Structural progression was assessed by the total hand damage score (determined by bone erosion and bone proliferation in fingers 2–5). Subgroup analyses based on BL disease activity as measured

by Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA) were performed for key endpoints.

Results:

A total of 122 pts enrolled and received APR. Mean age was 47 years, 55% were women, and mean duration of PsA was 1.9 years. The Full Analysis Set (FAS) included 98 pts evaluable for the primary endpoint (having BL and Week 24 data); 4 had major protocol deviations and 94 were evaluable as part of the per protocol (PP) population. The least- squares (LS) mean (95% CI) change from BL in the composite inflammation score of BME, synovitis, and tenosynovitis as assessed by PsAMRIS (FAS) was -2.32 (-4.73, 0.09) at Week 24 and -2.91 (-5.45, -0.37) at Week 48 (Figure). In the PP population, the LS mean (95% CI) change from BL in the composite score at Weeks 24 and 48 indicated a significant reduction of disease activity (Figure). Significant improvements from BL were seen in total inflammation scores (BME + synovitis + tenosynovitis + periarticular inflammation) in the FAS (Figure). The structural outcome indicated by the total hand damage score, including bone erosion, showed no significant change from BL to Week 48 (Figure). Pts also experienced significant improvements from BL in cDAPSA at Weeks 24 and 48 (Figure).

Subgroup analyses based on disease activity at BL showed significant improvements from BL in inflammation in pts with moderate disease activity (ModDA; cDAPSA score >13 to ≤27) and no significant change from BL in total damage (Figure). Though it was insignificant, pts with high disease activity (HDA; cDAPSA score >27) did have improvement from BL in inflammation indices (Figure).

Common treatment-emergent adverse events were diarrhea (33.6%), nausea (12.3%), headache (10.7%), nasopharyngitis (7.4%), and dyspepsia (6.6%). No new safety signals were identified.

Conclusion:

Pts with PsA treated with APR had improvements in both clinical indices and objective MRI indices of inflammation assessed by PsAMRIS in the target hand at Week 24 and Week 48, confirming an effect of APR on clinical and inflammatory manifestations of PsA. Pts with ModDA seemed to have greater improvement from BL in MRI inflammation scores than pts with HDA. No significant structural progression was observed. These results offer important insights on the effect of apremilast in PsA and highlight the value of using MRI and PsAMRIS as measures of inflammatory disease activity and change following treatment.

Congrats to the Team on BSI ISO13485 re-certification for DYNAMIKA!

Congrats to the Team on BSI ISO13485 re-certification for DYNAMIKA!

Congrats to the Team on BSI ISO13485 re-certification for DYNAMIKA!

Congratulations to IAG’s technical and quality teams for holding successful audit meetings with British Standards Institute (BSI) and receiving ISO13485 re-certification.

‘Maintenance of the highest technical standards is paramount to our company’s NDA!’ said Prof. Dehmeshki, Chief Technology Officer.

‘At IAG, we work to bring both CFR21 part 11 and ISO13485 quality standards into our day-to-day service and technology development, thus providing our clients with highest possible level of quality,’ said Max Feltham, IAG’s Quality Manager.

IAG’s DYNAMIKA platform is a unique comprehensible software for robust imaging data management in multi-centre trial setting and central review. Uniquely in the clinical research services industry, this is one software system to control trial progress, conduct central reads and, when needed, use built-in AI for earlier read-outs and decision support.

Use of DYNAMIKA, compliant to the industry’s highest quality certification as an integral  part of our CFR21 part 11 clinical trial process, enables IAG teams to deliver high quality results, even when managing complex clinical trials that require use of advanced imaging, technical solutions and Artificial Intelligence.

Moreover, having ISO13485 certification enables IAG to develop and release into clinical use novel methodologies, such as our AI-powered histology tool or the newest endpoint for scleroderma DAVIX.

‘We see DYNAMIKA as a unique bridge between clinical trials and clinical practice worlds. It is not trivial to translate the results of clinical trials into clinical practice. Here at IAG, we can power our pharmaceutical partners to do just that, said Dr. Olga Kubassova, IAG’s CEO.

Congratulations to the team, who will continue following ISO13485 and 21 CFR Part 11 and proceed with powering the best of pharmaceutical development, from phase 1-4!

Read more: DYNAMIKA, drugdevelopment, clinicaltrials, medicaldevice, MRI, CT, X-ray, PET, immunoPET, SPECT, US, histology, and fluoroscopy, imaging,

Read more about IAG’s expertise in Your Therapeutic Area.

Reach our to imaging.experts@ia-grp.com

About IAG, Image Analysis Group

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.

The use of novel image analysis methodologies will allow the partners to address complex issues such as pseudo-progression and quantitatively measure the treatment response, thus deploying a truly precision medicine approach to accurately monitor patient outcomes.

IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

About ISO

ISO 13485, Medical devices — Quality management systems — Requirements for regulatory purposes, is the International Standard for quality management systems for the medical devices sector. Published in 2016, it is designed to work with other management systems in a way that is efficient and transparent. The standard, which is now in its third edition, received strong support from the FDA, in line with its drive for global convergence of medical device regulatory processes.

The announcement by the FDA that it will use ISO 13485 in replacing its current quality system regulation, is an important next step in the recognition this standard has already gained globally.

News

Just published: AI Scoring System for Histology Review in Ulcerative Colitis

Published in April 2024 in United European Gastroenterol Journal,

Meet IAG at DDW 2024: AI and Precision Medicine in Ulcerative Colitis

Digestive Disease Week (DDW) meeting, Washington 18-21 May 2024

Webinar: Role of Artificial Intelligence in Imaging of Osteoarthritis

Discuss role of medical imaging and AI in drug development and clinical practice.

Meet IAG’s Musculoskeletal Expert Team at OARSI’24

Join our team to discuss imaging and AI in osteoarthritis drug development.

Events

AltruBio and IAG, Image Analysis Group Announce Partnership

AltruBio and IAG, Image Analysis Group Announce Partnership

AltruBio and IAG, Image Analysis Group Announce Partnership

SAN FRANCISCO, May 08, 2023 – AltruBio Inc. (“AltruBio” or “the Company”), a clinical-stage biotech company specializing in the development of novel therapeutics for the treatment of immunological diseases with high unmet medical needs, today announced a joint poster presentation with their partner Image Analysis Group (IAG) at the Digestive Disease Week® conference, held at McCormick Place in Chicago, IL, from May 6-9, 2023.

David T. Rubin, M.D., Professor of Medicine and Pathology at the University of Chicago and AltruBio Scientific Advisory Board member, will present proof of concept data utilizing a novel AI-powered method developed by IAG for the analysis of patient tissue from AltruBio’s Phase 2b open label study of immune checkpoint enhancer (ICE) ALTB-168, in patients with moderately to severely active anti-TNFα and/or anti-integrin refractory ulcerative colitis (UC).

“Using AI tools for histology simplifies the interpretation of histological samples and offers promise in establishing a new gold standard of histological assessment in clinical trials, as well as providing earlier signals for interpretation beneficial to both patients and scientists,” said Dr. Rubin.

Jesse Hall, M.D., Chief Medical Officer of AltruBio, added,

“IAG’s AI-powered technology accurately supports histological assessment of treatment response to our ICE in development. We plan to continue clinical validation of targeting PSGL-1 to treat autoimmune and inflammatory diseases and share further progress this year.”

Key data highlights include an 87% correlation between AI Tool-determined Nancy Indices and those conducted by an expert pathologist. The AI Tool also demonstrated a 93% decrease in automatically detected neutrophils for subjects who achieved clinical remission.

Poster Presentation Details:

Session Title: AGA IBD: Disease Activity Assessment Session Date & Time: May 8, 2023 from 12:30 PM to 1:30 PM CDT (UTC –5) Presentation Title: A Novel AI Tool is Accurate at Interpreting Histology and Detects Response to ALTB-168 Therapy in Patients with Moderate to Severe Ulcerative Colitis: Proof of Concept

About AltruBio Inc.

AltruBio is a privately held biotechnology company headquartered in San Francisco that focuses on developing novel therapeutics for the treatment of immunological diseases with high unmet medical needs. Its first-generation molecule, ALTB-168, has achieved proof of mechanism in four autoimmune and inflammatory diseases. The next-generation ICE, ALTB-268, is currently being evaluated in a Phase 1 clinical trial.

About Digestive Disease Week Digestive Disease Week®

DDW is the largest international gathering of physicians, researchers, and academics in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. The conference showcases more than 3,100 abstracts and hundreds of lectures on the latest advances in GI research, medicine, and technology. More information can be found at www.ddw.org.

About IAG, Image Analysis Group:

IAG, Image Analysis Group is a unique clinical development partner to life sciences companies. We broadly leverage our proprietary image analysis methodologies, power of our cloud platform DYNAMIKA, years of experience in AI and Machine Learning as well as bespoke co-development business models to ensure higher probability for promising therapeutics to reach the patients. Our independent Bio-Partnering division fuses risk-sharing business models and agile culture to accelerate novel drug development. wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

News

Just published: AI Scoring System for Histology Review in Ulcerative Colitis

Published in April 2024 in United European Gastroenterol Journal,

Meet IAG at DDW 2024: AI and Precision Medicine in Ulcerative Colitis

Digestive Disease Week (DDW) meeting, Washington 18-21 May 2024

Webinar: Role of Artificial Intelligence in Imaging of Osteoarthritis

Discuss role of medical imaging and AI in drug development and clinical practice.

Meet IAG’s Musculoskeletal Expert Team at OARSI’24

Join our team to discuss imaging and AI in osteoarthritis drug development.

Events

MIMEDX and IAG Partner to Support Knee Osteoarthritis Ph 3 Clinical Trial Program

MIMEDX and IAG Partner to Support Knee Osteoarthritis Ph 3 Clinical Trial Program

Image Analysis Group to Partner with MIMEDX in Support of MIMEDX’s Knee Osteoarthritis Clinical Trial Program

Image Analysis Group to Provide Imaging Strategy and Advanced Imaging Analytics in Support of MIMEDX’s Knee Osteoarthritis Clinical Trial Program

MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts and IAG, Image Analysis Group, a strategic bio-pharma imaging expert announce a partnership in the development of MIMEDX’s mdHACM.

The IAG team has significant experience in using medical imaging to support drug development.

‘We have significant evidence that mdHACM injected into the knees of people with OA provides lasting pain relief and improves function, and we believe it has potential as a DMOAD. MIMEDX has discovered how to preserve the remarkable healing properties of placental membranes when we produce mdHACM, and we have demonstrated that it contains many proteins that influence the biology of cartilage-forming cells and reduce inflammation. We believe these active proteins contribute to the striking, long-lasting benefits we have seen in patients receiving a single injection of mdHACM into their osteoarthritic knee. Following an extensive review and selection process, we are very excited to have world-class partners who are at the forefront of advancing meaningful medicines; working in collaboration accelerates our ability to gather quality data for our future Biologics License Application (BLA), and our potential to bring tremendous benefit for people living with OA.’ said Dr Robert B. Stein, M.D., Ph.D., MIMEDX President, Regenerative Medicine & Biologics Innovation.

About Image Analysis Group (IAG):

IAG, Image Analysis Group is a unique clinical development partner to life sciences companies. We broadly leverage our proprietary image analysis methodologies, power of our cloud platform DYNAMIKA, years of experience in AI and Machine Learning as well as bespoke co-development business models to ensure higher probability for promising therapeutics to reach the patients. Our independent Bio-Partnering division fuses risk-sharing business models and agile culture to accelerate novel drug development. wp1.ia-grp.com

About MIMEDX: 

MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental tissue engineering, we have both a commercial business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments.

For more information, please reach out to: imaging.experts@ia-grp.com

READ NEXT CASE STUDY >

Supporting Advance Imaging Research in Psoriatic Arthritis Treatment

Supporting Advance Imaging Research in Psoriatic Arthritis Treatment

Academic and Clinical Opinion Leaders and Image Analysis Group Collaborate to Advance Research in Psoriatic Arthritis Treatment.

London, UK — Image Analysis Group (wp1.ia-grp.com), a pioneer in medical imaging research and analysis, have joined forces in a strategic collaboration with renowned academic and clinical opinion leaders aimed at advancing research in the treatment of Psoriatic Arthritis, study MOSAIC, ClinicalTrials.gov Identifier: NCT03783026.

Amgen, known for its commitment to innovative therapies, recently presented the results of MOSAIC and its clinically relevant research findings on Otezla (Apremilast) in Psoriatic Arthritis during the European League Against Rheumatism (EULAR) 2023 annual meeting. The study, titled “Apremilast Reduces Inflammation as Measured by MRI of the Hand in Patients With Psoriatic Arthritis: Primary Results from the Phase 4 MOSAIC Study,” showcased the potential of Apremilast in reducing inflammation, as assessed through MRI scans of the hand.

This work is done in collaboration with MOSAIC study Primary Investigators Prof. Mease and Prof. Ostergaard, number of academic institutions and Image Analysis Group, an organization specializing in advanced medical imaging analysis and research.

This phase 4 trial and collected imaging and clinical data mark a significant step forward in drug developers’ mission to improve the lives of individuals affected by Psoriatic Arthritis. By harnessing the expertise and cutting-edge methodologies and advanced technology platform DYNAMIKA, Image Analysis Group and the collaborators aim to explore and quantify the impact of Apremilast on patients’ lives.

Image Analysis Group’s dedication to developing precise and comprehensive imaging solutions aligns seamlessly with Amgen’s commitment to scientific innovation, said Dr. Olga Kubassova, CEO of IAG.

We are excited to work in this trial with this dedicated group of people, so that our expertise in medical imaging analysis can support understanding and treatment of Psoriatic Arthritis, said Prof. Mikael Boesen, Sn Therapeutic Lead for Musculoskeletal Research at IAG and Head of musculoskeletal imaging and research, Bispebjerg and Frederiksberg Hospital, Radiology, Department of Overlæge, Professor, Bispebjerg and Frederiksberg Hospital, The Parker Institute , Denmark.

This work with Amgen and all collaborators signifies a shared vision of improving patient outcomes through innovation and imaging research.

For media inquiries, interview requests, or further information about this collaboration, please contact

imaging.experts@ia-grp.com

About Image Analysis Group: Image Analysis Group (wp1.ia-grp.com) is a leading provider of advanced medical imaging research and analysis services. With a focus on precision and scientific rigor, Image Analysis Group collaborates with pharmaceutical companies, research institutions, and healthcare providers to enhance the understanding of diseases and support the development of novel treatments.

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

READ NEXT CASE STUDY >

Supportting Advance Imaging Research in Women’s Reproductive Health

Supportting Advance Imaging Research in Women’s Reproductive Health

Ferring Pharmaceuticals and Image Analysis Group Collaborate to Advance Research in the complex field of pregnancy.

London, UK — Image Analysis Group (wp1.ia-grp.com), a leader in medical imaging, have joined forces in a strategic collaboration with Ferring Pharmaceuticals to advance Women’s Reproductive Health through AI-driven medical image analysis.

Dr. Philippe Pinton, Senior Vice President, Head of Clinical and Translational Sciences, Global R&D at Ferring Pharmaceuticals, stated, “Our collaboration with IAG is a testament to our commitment to AI-driven research in the complex field of pregnancy.”

Dr. Olga Kubassova, CEO of IAG, added, “We are excited to support the Ferring team in leveraging AI to gain deeper insights into women’s reproductive health, ultimately aiming to enhance the chances of a healthy pregnancy for women globally.”

IAG’s mission is to assist pharmaceutical partners in efficiently developing transformative medicines. This is achieved through their expertise in medical imaging and AI, utilizing their proprietary platform, DYNAMIKA. This platform is designed to efficiently manage large volumes of imaging data in multi-centre trials and incorporates integrated AI modules. The partnership promises innovative approaches to improve women’s health worldwide.

For media inquiries, interview requests, or further information about this collaboration, please contact

imaging.experts@ia-grp.com

About Image Analysis Group: Image Analysis Group (wp1.ia-grp.com) is a leading advanced medical imaging research and analysis services provider. With a focus on precision and scientific rigour, Image Analysis Group collaborates with pharmaceutical companies, research institutions, and healthcare providers to enhance the understanding of diseases and support the development of novel treatments.

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

READ NEXT CASE STUDY >